Pacific Biosciences of California: Sell Before Potential Reverse Split
Source: SeekingAlpha
2025-06-02 06:01:11 ET
Summary
- Pacific Biosciences of California's stock has plummeted from over $50 to near $1, reflecting severe operational and financial struggles.
- Revenue growth in 2025 could be pressured by US government budget cuts, and management has already lowered its yearly guidance range.
- Cash burn is expected to continue into 2027, and a debt-heavy balance sheet could pressure sentiment in the coming years.
...
Read the full article on Seeking Alpha
For further details see:
Pacific Biosciences of California: Sell Before Potential Reverse Split
Pacific Biosciences of California Inc.
NASDAQ: PACB
PACB Trading
4.72% G/L:
$1.33 Last:
3,202,013 Volume:
$1.30 Open:
PACB Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 24, 2026 09:05:00 am
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
February 18, 2026 04:05:00 pm
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
PACB Stock Data
$549,471,524
294,359,745
0.64%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
